Seladelpar

Seladelpar
Clinical data
Trade namesLivdelzi
Other namesMBX-8025; RWJ-800025
AHFS/Drugs.comLivdelzi
License data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
  • 2-[4-[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H23F3O5S
Molar mass444.47 g·mol−1
3D model (JSmol)
  • CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C
  • InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1
  • Key:JWHYSEDOYMYMNM-QGZVFWFLSA-N

Seladelpar, sold under the brand name Livdelzi, is a medication used for the treatment of primary biliary cholangitis.[1] It is used as the lysine dihydrate salt.[1] It is a PPARδ receptor agonist.[1][2][3] The compound was licensed from Janssen Pharmaceutica NV.[4]

Seladelpar was approved for medical use in the United States in August 2024.[1][5]

  1. ^ a b c d e "Livdelzi- seladelpar lysine capsule". DailyMed. 14 August 2024. Retrieved 5 September 2024.
  2. ^ Billin AN (October 2008). "PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home". Expert Opinion on Investigational Drugs. 17 (10): 1465–1471. doi:10.1517/13543784.17.10.1465. PMID 18808307. S2CID 86564263.
  3. ^ Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, et al. (September 2011). "MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin". The Journal of Clinical Endocrinology and Metabolism. 96 (9): 2889–2897. doi:10.1210/jc.2011-1061. PMID 21752880.
  4. ^ "Targeting Mixed Dyslipidemia and Metabolic Syndrome". Metabolex, Inc. 2005. Archived from the original on 17 October 2006.
  5. ^ "Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA" (Press release). Gilead. 14 August 2024. Retrieved 15 August 2024 – via Business Wire.